Replies to post #1676 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Other PBMs haven't yet released their planned 2019 formularies, as far as I know.

ABBV has said all along that Mavyret's focus in the US market is on the government segment of the market, where PBMs play no role. So, even if CVS or another large PBM were to shun Mavyret in 2019, the damage wouldn't be that bad.